Salmeterol is a long-acting b2-agonist, widely used as an inhaled treatment of asthma and chronic obstructive pulmonary disease. It has very high b2-affinity (log KD 28.95) and is very selective for the b2-adrenoceptor (1000-fold selectivity over the b1-adrenoceptor). This study used a mutagenesis approach to determine the exact amino acids in the human b2-adrenoceptor responsible for this very...

Impairment of health after overcoming the acute phase COVID-19 is being observed more and frequently. Here different symptoms neurological and/or cardiological origin have been reported. With symptoms, which are very similar to ones reported but not caused by SARS-CoV-2, occurrence functionally active autoantibodies (fAABs) targeting G-protein coupled receptors (GPCR-fAABs) has discussed be inv...

Salmeterol is a long-acting β2-agonist, widely used as an inhaled treatment of asthma and chronic obstructive pulmonary disease. It has very high β2-affinity (log KD -8.95) and is very selective for the β2-adrenoceptor (1000-fold selectivity over the β1-adrenoceptor). This study used a mutagenesis approach to determine the exact amino acids in the human β2-adrenoceptor responsible for this very...

Beta3-Adrenoceptors are involved in the control of catecholamine-induced lipolysis in rodent adipose tissues. The expression and function of human beta3-adrenoceptors were investigated in subcutaneous white adipocytes of young healthy women. In these cells, beta3-adrenoceptor mRNAs represent 20% of total amount of beta-adrenoceptor transcripts and less than half of beta1-adrenoceptor transcript...

Using the cannula inserting method, vasoconstrictor responses to 1-adrenoceptor agonists (noradrenaline [NA], phenylephrine [PE] and methoxamine [ME]) and effects of 1-adrenoceptor antagonists (WB4101, chloroethylclonidine [CEC] and BMY7378) were investigated in isolated and perfused rat common carotid arteries. The rank order of agonist potency and efficacy was NA PE ME. Either WB4101 or BYM73...

Many clinically used drugs are G-protein-coupled receptor (GPCR) antagonists and are given long-term to prevent receptor activation by endogenous agonists. Most GPCR antagonists are considered to have little agonist efficacy of their own. However, many beta antagonists do stimulate very small beta(2) adrenoceptor-mediated cAMP responses, but these responses become substantial at the level of cA...